NVO vs. AZN
Compare and contrast key facts about Novo Nordisk A/S (NVO) and AstraZeneca PLC (AZN).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVO or AZN.
Correlation
The correlation between NVO and AZN is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVO vs. AZN - Performance Comparison
Key characteristics
NVO:
0.15
AZN:
-0.01
NVO:
0.44
AZN:
0.13
NVO:
1.05
AZN:
1.02
NVO:
0.14
AZN:
-0.00
NVO:
0.35
AZN:
-0.01
NVO:
12.98%
AZN:
10.51%
NVO:
30.53%
AZN:
20.68%
NVO:
-71.30%
AZN:
-48.94%
NVO:
-29.32%
AZN:
-26.46%
Fundamentals
NVO:
$486.49B
AZN:
$205.69B
NVO:
$2.99
AZN:
$2.07
NVO:
36.12
AZN:
32.00
NVO:
1.61
AZN:
0.71
NVO:
$270.58B
AZN:
$52.12B
NVO:
$229.07B
AZN:
$39.61B
NVO:
$135.97B
AZN:
$16.91B
Returns By Period
In the year-to-date period, NVO achieves a 1.09% return, which is significantly higher than AZN's -2.25% return. Over the past 10 years, NVO has outperformed AZN with an annualized return of 19.11%, while AZN has yielded a comparatively lower 9.49% annualized return.
NVO
1.09%
0.79%
-26.36%
3.23%
31.11%
19.11%
AZN
-2.25%
1.00%
-17.47%
0.08%
7.60%
9.49%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVO vs. AZN - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NVO vs. AZN - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 1.40%, less than AZN's 2.30% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 1.40% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% | 1.72% |
AZN AstraZeneca PLC | 2.30% | 2.15% | 2.14% | 2.40% | 2.80% | 2.81% | 3.61% | 3.95% | 5.01% | 4.06% | 3.98% | 4.72% |
Drawdowns
NVO vs. AZN - Drawdown Comparison
The maximum NVO drawdown since its inception was -71.30%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for NVO and AZN. For additional features, visit the drawdowns tool.
Volatility
NVO vs. AZN - Volatility Comparison
Novo Nordisk A/S (NVO) has a higher volatility of 7.70% compared to AstraZeneca PLC (AZN) at 6.71%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NVO vs. AZN - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities